The First Study on Therapeutic Efficacies of a Vascular Disrupting Agent CA4P Among Primary Hepatocellular Carcinomas With a Full Spectrum of Differentiation and Vascularity: Correlation of MRI-microangiography-histopathology in Rats

International Journal of Cancer - United States
doi 10.1002/ijc.31567
Full Text
Abstract

Available in full text

Date
Authors
Publisher

Wiley

Related search

Pulmonary Neuroendocrine Carcinomas—evidence for a Spectrum of Differentiation

Virchows Archiv
MedicineForensic MedicinePathologyCell BiologyMolecular Biology
2018English

Evaluation of Sydnone-Based Analogs of Combretastatin A-4 Phosphate (CA4P) as Vascular Disrupting Agents for Use in Cancer Therapy

ChemMedChem
Organic ChemistryMolecular MedicinePharmacologyBiochemistryToxicologyDrug DiscoveryPharmaceutics
2018English

Phase I and Pharmacokinetic Study of the Vascular‐disrupting Agent CKD‐516 (NOV120401) in Patients With Refractory Solid Tumors

Pharmacology Research and Perspectives
ToxicologyNeurologyPharmaceuticsPharmacology
2020English

Hydroxysafflor Yellow A: A Promising Therapeutic Agent for a Broad Spectrum of Diseases

Evidence-based Complementary and Alternative Medicine
Alternative MedicineComplementary
2018English

Whole-Genome Sequencing of Matched Primary and Metastatic Hepatocellular Carcinomas

BMC Medical Genomics
Genetics
2014English

Primary Cardiac Angiosarcoma. Histopathology Imaging Correlation

Journal of Cardiology Cases
Cardiovascular MedicineCardiology
2017English

A Full Spectrum of Diketene Derivatives for a Full Spectrum of Needs.

Chemical and Engineering News
Chemical Engineering
1984English

Risk of Second Primary Cancers Among Patients With a First Primary Gastric Cancer: A Population-Based Study in North Portugal

Cancer Epidemiology
Cancer ResearchEpidemiologyOncology
2017English

On Vascular Tumour and Morbid Vascularity of the Female Urethra

BMJ
1852English

Amanote Research

Note-taking for researchers

Follow Amanote

© 2024 Amaplex Software S.P.R.L. All rights reserved.

Privacy PolicyRefund Policy